Consun held the 2023 Summary and Evaluation Conference and the 2024 Planning Conference.
Consun Pharma 1681.HK
Tang Ning, Vice President of Consun, stated: “In 2023, the group worked diligently and energetically, overcoming obstacles and delivering a satisfactory achievement with effort and sweat. Thanks to the collective efforts of everyone, the group's sales revenue experienced solid growth.”
“The flagship product, Niaoduqing Granules, maintained a leading position in the category of modern oral medications for kidney diseases. The product line for women and children, Yuanli Kang®, showed robust growth, while imaging lines and over-the-counter products progressed in tandem. At the same time, both Consun and the company and products of Yulin have received numerous awards, fully highlighting the market reputation of the Consun and Yulin product series”.